Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis.

Maria Francesca CabidduAlberto RussiLucia AppolloniDaniele MengatoMarco Chiumente

Published in: European journal of hospital pharmacy : science and practice (2020)

A total of 11 randomised studies for 100 609 patients were analysed. Our meta-analysis showed a statistically significant reduction in mortality due to cardiovascular issues (RR=0.937; 95% CI: 0.88 to 0.98; P=0.018). The TSA indicated that no further trials are needed to better evaluate the efficacy of PUFAs in preventing death related to CVD.

Keyphrases

systematic review
case control
end stage renal disease
clinical trial
meta analyses
cardiovascular disease
study protocol
chronic kidney disease
newly diagnosed
open label
prognostic factors
peritoneal dialysis
phase iii
phase ii
double blind
placebo controlled
cardiovascular risk factors